JP2023535027A - ピルビン酸キナーゼを活性化するための組成物及び方法 - Google Patents

ピルビン酸キナーゼを活性化するための組成物及び方法 Download PDF

Info

Publication number
JP2023535027A
JP2023535027A JP2023504298A JP2023504298A JP2023535027A JP 2023535027 A JP2023535027 A JP 2023535027A JP 2023504298 A JP2023504298 A JP 2023504298A JP 2023504298 A JP2023504298 A JP 2023504298A JP 2023535027 A JP2023535027 A JP 2023535027A
Authority
JP
Japan
Prior art keywords
optionally substituted
cycloalkyl
heterocycle
monocyclic
tricyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535027A5 (cg-RX-API-DMAC7.html
Inventor
ベシリ,チャウリ
レック,ジェイソン
ウーベン,トーマス
ウォッチ,ブレナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of JP2023535027A publication Critical patent/JP2023535027A/ja
Publication of JP2023535027A5 publication Critical patent/JP2023535027A5/ja
Priority to JP2026020484A priority Critical patent/JP2026097841A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023504298A 2020-07-21 2021-07-21 ピルビン酸キナーゼを活性化するための組成物及び方法 Pending JP2023535027A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026020484A JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054478P 2020-07-21 2020-07-21
US63/054,478 2020-07-21
PCT/US2021/042489 WO2022020424A1 (en) 2020-07-21 2021-07-21 Compositions and methods for activating pyruvate kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026020484A Division JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2023535027A true JP2023535027A (ja) 2023-08-15
JP2023535027A5 JP2023535027A5 (cg-RX-API-DMAC7.html) 2024-07-03

Family

ID=79728915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023504298A Pending JP2023535027A (ja) 2020-07-21 2021-07-21 ピルビン酸キナーゼを活性化するための組成物及び方法
JP2026020484A Pending JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026020484A Pending JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Country Status (7)

Country Link
US (1) US20230374017A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185293A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023535027A (cg-RX-API-DMAC7.html)
CN (1) CN116249531A (cg-RX-API-DMAC7.html)
AU (1) AU2021311597B2 (cg-RX-API-DMAC7.html)
CA (1) CA3183980A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022020424A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539573A (ja) * 2021-09-30 2024-10-29 シトリクス・セラピューティクス・リミテッド 新規化合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
CN118434720A (zh) 2021-12-22 2024-08-02 西特瑞治疗有限公司 作为丙酮酸激酶调节剂的酞嗪衍生物
WO2023211999A1 (en) * 2022-04-29 2023-11-02 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173415A2 (en) * 2008-10-09 2017-05-31 The U.S.A. as represented by the Secretary, Department of Health and Human Services Activators of human pyruvate kinase
WO2019035865A1 (en) * 2017-08-15 2019-02-21 Agios Pharmaceuticals Inc. MODULATORS OF PYRUVATE KINASE AND THEIR USE
WO2020167976A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137320A1 (en) * 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
US8563580B2 (en) * 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
EP2968323A4 (en) * 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
US12233063B2 (en) * 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173415A2 (en) * 2008-10-09 2017-05-31 The U.S.A. as represented by the Secretary, Department of Health and Human Services Activators of human pyruvate kinase
WO2019035865A1 (en) * 2017-08-15 2019-02-21 Agios Pharmaceuticals Inc. MODULATORS OF PYRUVATE KINASE AND THEIR USE
WO2020167976A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMINFORM, vol. 21, no. 38, JPN6025032414, 1990, pages 102 - 104, ISSN: 0005661478 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539573A (ja) * 2021-09-30 2024-10-29 シトリクス・セラピューティクス・リミテッド 新規化合物

Also Published As

Publication number Publication date
CA3183980A1 (en) 2022-01-27
EP4185293A1 (en) 2023-05-31
AU2021311597B2 (en) 2026-08-06
US20230374017A1 (en) 2023-11-23
EP4185293A4 (en) 2025-01-15
JP2026097841A (ja) 2026-06-16
WO2022020424A1 (en) 2022-01-27
CN116249531A (zh) 2023-06-09
AU2021311597A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP6767875B2 (ja) Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
KR102797536B1 (ko) PI3Kα 억제제 및 이의 사용 방법
CN116723843A (zh) 用于治疗和/或预防癌症的sos1抑制剂的药物组合
CA3124678A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
KR101871436B1 (ko) 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
CA3142340A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CN116249531A (zh) 用于激活丙酮酸激酶的组合物和方法
KR102211310B1 (ko) [1,2,4]트라이아졸[4,3-에이]피리딘 유도체, 그의 제조 방법 또는 그의 의학적 용도
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
WO2014055955A1 (en) Gdf-8 inhibitors
CN102399218A (zh) 一类并合三杂环及其作为pi3k抑制剂的用途
JP2011525535A (ja) PI3K/mTOR阻害剤
EP1567527A1 (en) Condensed pyrazolo derivatives
CN119013279A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
CA3129829A1 (en) Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
TW200925160A (en) Fused heterocyclic compound
KR20140014104A (ko) 치환된 이미다조퀴놀린 유도체
KR20230022433A (ko) Gpr65의 조절제로서 n-(페닐아미노카보닐) 테트라하이드로-이소퀴놀린 및 관련 화합물
JP2025534283A (ja) AhRシグナル伝達の調節に有用な化合物
HK40018685B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
HK40018685A (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
HK1220409B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260310